Keyphrases
Type 2 Diabetic Patients
100%
Atrial Fibrillation
100%
Population-based Cohort Study
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Antidiabetic Drugs
85%
Confidence Interval
57%
Risk Reduction
42%
Heart Failure
42%
Drug Class
28%
Body Mass Index
28%
Diabetes Duration
28%
Hemoglobin A1c (HbA1c)
28%
Hazard Ratio
14%
First-ever
14%
Cox Regression Analysis
14%
Effect Modification
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Population-based
14%
Stratified Analysis
14%
New User
14%
Time-dependent Covariates
14%
Clinical Practice Research Datalink
14%
Treatment History
14%
Glucose-lowering Drugs
14%
Non-insulin
14%
Cardiac Effects
14%
Renal Effects
14%
Cardiac Death
14%
Atrial Flutter
14%
New Antidiabetic Drugs
14%
Active Comparator
14%
Adjusted Hazard Ratio
14%
Value Interactions
14%
Medicine and Dentistry
Cohort Analysis
100%
Antidiabetic Agent
100%
Atrial Fibrillation
100%
Patient with Type 2 Diabetes
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Congestive Heart Failure
42%
Hazard Ratio
28%
Diabetes
28%
Body Mass Index
28%
Hemoglobin A1c
28%
Proportional Hazards Model
14%
Maturity Onset Diabetes of the Young
14%
Atrial Flutter
14%
Heart Death
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Antidiabetic Agent
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Atrial Fibrillation
100%
Non Insulin Dependent Diabetes Mellitus
100%
Congestive Heart Failure
42%
Hemoglobin A1c
28%
Heart Atrium Flutter
14%
Heart Death
14%
Biochemistry, Genetics and Molecular Biology
Cohort Study
100%
Atrial Fibrillation
100%
Sodium-Glucose Cotransporter 2 Inhibitors
100%
Body Mass
33%
Atrial Flutter
16%